Disclosure Plus

Vitzro Nextech Co., LTD Secures 11.6 Billion Won Government-Funded Project

Park Sun-Yeop
2026-06-23 10:32:24
[Edaily Reporter Park Sun-Yeop ] Vitzro Nextech Co., LTD has acquired the remaining R&D tasks and related deliverables from DAWONSYS Co., LTD’s government-funded project.
#Vitzro Nextech Co., LTD announced on the 23rd that it has acquired the remaining R&D tasks and related deliverables from DAWONSYS Co., LTD(068240), which was selected as a joint R&D institution for a government-funded project overseen by the Korea Institute for Industrial Technology Planning and Evaluation (KIITPE), an agency under the Ministry of Trade, Industry and Energy.
The project in question is titled “Development of Technology for Producing High-Value-Added Chemical Products from By-Product Gases of the Naphtha Cracking Process.” The specific R&D tasks involve the design, fabrication, demonstration, and operational evaluation of a plasma system for producing carbon black.
The transfer was finalized on the 22nd. The joint R&D institutions involved are the transferee, Vitzro Nextech Co., LTD, and the transferor, DAWONSYS Co., LTD.
The total research budget is 11,612.8 million won, which represents 19.7% of Vitzro Nextech Co., LTD.’s equity capital of 58,953.3 million won. Of this amount, government funding totals 7,778.8 million won, equivalent to 13.2% of equity capital.
The project will run from the 15th of this month through December 31, 2030.

Economy

Corporation

IT·Science

Economy

[VC's Pick] Big Money Flows into Smart 'Medical AI and Robotics' Technologies That Replace Human Hands

This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
2026-11-21 10:04:03

Corporation

Celltrion Sees Full-Scale Results from Direct Sales in the U.S. … “Projected Operating Profit of 2.4 Trillion Won Next Year”

Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
2026-11-21 06:01:02

IT·Science

Penetrium Bioscience and AprilBio Rally as AriBio-Linked Stocks Diverge [K-Bio Pulse]

South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…
2026-11-21 08:17:02